Table 3.
The results of virologic and serologic testing of seven equine West Nile neuroinvasive disease cases in Austria, 2016–2018
| Case No. | |||||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| Nucleic acid test (Blood/CSF/Brain) | |||||||
| RT‐qPCR WNV | +/−/nt | −/−/+ | −/−/nt | −/−/+ | −/−/nt | nt/−/−a | nt/−/+ |
| RT‐PCR Flavivirus | −/−/nt | −/−/+ | −/−/nt | −/−/+ | −/−/nt | −/−/−a | −/−/+ |
| RT‐qPCR TBEV | −/−/nt | −/−/nt | −/−/nt | −/−/nt | −/−/nt | nt/nt/nt | nt/nt/nt |
| RT‐qPCR USUV | −/−/nt | −/−/nt | −/−/nt | −/−/nt | −/−/nt | nt/nt/nt | nt/nt/nt |
| Antibody test (Blood/CSF) | |||||||
| IgM WNVb | +/− | −/− | +/+ | +/+ | +/− | +/nt | +/nt |
| IgG WNVb | +/− | +/+ | +/+ | +/− | +/+ | +/nt | +/nt |
| PRNT80 WNVc | 1:20/nt | 1:20/− | 1:20/− | 1:20/nt | 1:40/− | nt/nt | nt/nt |
| PRNT80 TBEVc | −/nt | −/− | −/− | −/nt | −/− | nt/nt | nt/nt |
| PRNT80 USUVc | −/nt | −/− | −/− | −/nt | −/− | nt/nt | nt/nt |
| SNT WNVd | 1:20 | nt | − | 1:120 | − | 1:20 | 1:20 |
Abbreviations: +, positive; −, negative; nt, not tested; TBEV, Tick‐borne encephalitis virus; USUV, Usutu virus; WNV, West Nile virus.
a
Weak positive.
b
ID Screen® commercial ELISA kits from ID Vet.
c
Endpoint titres are reported for 80% plaque reduction neutralization assay (PRNT80).
d
Endpoint serum neutralization titres (SNT) are reported.